by The global non-opioid pain treatment market size accounted for US$ 42.3 Bn in 2022 and is projected to reach around USD 79.7 Bn by 2032, growing at a CAGR of 6.54% from 2023 to 2032.
Report Summary
The global non-opioid pain treatment market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the non-opioid pain treatment market across the globe.
A comprehensive estimate on the non-opioid pain treatment market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of non-opioid pain treatment during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2616
Non-opioid Pain Treatment Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 45.07 Billion |
| Market Size by 2032 | USD 79.7 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.54% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Class, By Pain Type, By Route of Administration and By Distribution Channel |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized non-opioid pain treatment market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Submarine Cable System Market Size To Cross USD 41.02 Bn By 2032
Non-opioid Pain Treatment Market Players
The report includes the profiles of key non-opioid pain treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Dr. Reddy’s Laboratories Ltd
- Sun Pharmaceutical Industries Ltd
- GSK plc.
- Pfizer Inc.
- Perrigo Company plc,
- LNK International, Inc.
- Cipla Inc.
- Johnson & Johnson Services, Inc.
- Pacira Pharmaceuticals, Inc.
- Pierrel
Market Segmentation
By Drug Class
- NSAIDs
- Selective COX-2 Inhibitors
- Non-Selective NSAIDs
- Acetaminophen
- Local Anesthetics
- Others
By Pain Type
- Chronic Pain
- Neuropathic Pain
- Inflammatory Conditions
- Post-operative Pain
- Cancer Pain
- Others
By Route of Administration
- Oral
- Topical
- Injectable
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- The Middle East and Africa
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Non-opioid Pain Treatment Market
5.1. COVID-19 Landscape: Non-opioid Pain Treatment Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Non-opioid Pain Treatment Market, By Drug Class
8.1. Non-opioid Pain Treatment Market, by Drug Class, 2023-2032
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Acetaminophen
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Local Anesthetics
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Non-opioid Pain Treatment Market, By Pain Type
9.1. Non-opioid Pain Treatment Market, by Pain Type, 2023-2032
9.1.1. Chronic Pain
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Post-operative Pain
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Cancer Pain
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Non-opioid Pain Treatment Market, By Route of Administration
10.1. Non-opioid Pain Treatment Market, by Route of Administration, 2023-2032
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Injectable
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Non-opioid Pain Treatment Market, By Distribution Channel
11.1. Non-opioid Pain Treatment Market, by Distribution Channel, 2023-2032
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Non-opioid Pain Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.1.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Pain Type (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 13. Company Profiles
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Limited
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Dr. Reddy’s Laboratories Ltd
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sun Pharmaceutical Industries Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GSK plc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Perrigo Company plc,
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. LNK International, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Cipla Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson Services, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
